Document:

ex10_2.htm

Exhibit 10.2

THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD, TRANSFERRED, HYPOTHECATED OR OTHERWISE DISPOSED OF BY THE HOLDER EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND IN COMPLIANCE WITH APPLICABLE SECURITIES LAWS OF ANY STATE WITH RESPECT THERETO OR IN ACCORDANCE WITH AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER THAT AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE AND ALSO MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH ANY APPLICABLE RULES OF THE SECURITIES AND EXCHANGE COMMISSION.

REGEN BIOLOGICS, INC.

12.00% Secured Convertible Note

No. S-__

	$ 	March 11, 2011

 

REGEN BIOLOGICS, INC., a Delaware corporation (the “Company”), for value received, hereby promises to pay to Sports Medicine Holding Company, LLC or its registered assigns the principal sum of $____, including interest (computed on the basis of a 360-day year of twelve 30-day months) on the unpaid principal balance hereof from the date of the Closing at the rate of interest (the “Interest Rate”) specified below.

 

1.           Interest hereon shall accrue at a rate of 12.00% per annum commencing on the date of the Closing and shall be payable, in arrears, on the Due Date.  Following the Due Date, interest hereon shall accrue at a rate of 12.00% per annum until paid in full.

 

2.           Payments of principal, interest and all other amounts due in respect hereof shall be made in immediately available U.S. Dollars at the address shown in the Register maintained by the Company for such purpose, in the manner and in accordance with the terms provided in the Subscription Agreement.

 

3.           This Note is one of an issue of 12.00% Secured Convertible Notes of the Company issued in an aggregate principal amount of up to $750,000, pursuant to the Subscription and Security Agreement, dated as of March 11, 2011 (as the same may be amended, restated or otherwise modified from time to time, the “Subscription Agreement”), among the Company and the original signatory thereto.  The holder of this Note is entitled to the benefits of the Subscription Agreement.  This Note is subject to the terms of the Subscription Agreement, and such terms are incorporated herein by reference.  Capitalized terms used herein and not defined herein have the meanings specified in the Subscription Agreement.

 

4.           This Note shall be convertible into shares of securities of the Company or ReGen AG on the terms and conditions set forth in the Subscription Agreement.

 

  

  

  

 

5.           This Note shall not confer any preemptive rights to its Holder.

 

6.           The Subscription Agreement contains provisions permitting the Issuer and the Holders of the Notes representing the Required Consent, to execute amendments adding any provisions to or changing in any manner or eliminating any of the provisions of the Subscription Agreement or modifying in any manner the rights of the Holders of the Notes, subject to any exceptions set forth in the Subscription Agreement.

 

7.           The Notes are issuable in fully registered form, without coupons, at the office or agency of the Issuer, and in the manner and subject to the limitations provided in the Subscription Agreement.  Notes may be exchanged for a like aggregate principal amount of Notes of any other authorized denominations.

 

8.           This Note is transferable only as specified in the Subscription Agreement, duly endorsed or accompanied by a written instrument of transfer duly executed by the holder of this Note or its attorney duly authorized in writing.

 

9.           THIS NOTE AND THE SUBSCRIPTION AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO ANY CONFLICTS OF LAW RULES THAT WOULD REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER JURISDICTION.

 

	 	 	REGEN BIOLOGICS, INC.	 
	 	 	 	 
	 	 	 	 
	
 

	 	 By: 	 	 
	 	 	Name: Gerald E. Bisbee, Jr., Ph.D. 	 
	 	 	Title:   President and Chief Executive Officer 

 

  

  

  

 

CONVERSION NOTICE

 

	
TO:

	
REGEN BIOLOGICS, INC.

 

The undersigned registered owner of this Note hereby irrevocably exercises the option to convert this Note, or the portion thereof below designated, into shares of equity securities in accordance with the terms of the Subscription Agreement referred to in this Note, and directs that the shares of equity securities, together with any check in payment for cash, if any, payable upon exchange or for fractional shares and any Notes representing any unconverted principal amount hereof, be issued and delivered to the registered holder hereof unless a different name has been indicated below.  Capitalized terms used herein but not defined shall have the meanings ascribed to such terms in the Subscription Agreement.  If shares or any portion of this Note not converted are to be issued in the name of a person other than the undersigned, the undersigned will provide the appropriate information below and pay all transfer taxes payable with respect thereto.

 

 

	Dated: 	 	 	 	Note No: S- ___
	 	 	 	 
	 	 	 Registered Holder:	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 Signature(s)	 
	 	 	 	 
	 	 	Signature(s) must be guaranteed by an “eligible guarantor institution” meeting the requirements of the Security Registrar, which requirements include membership or participation in the Security Transfer Agent Medallion Program (“STAMP”) or such other “signature guarantee program” as may be determined by the Security Registrar in addition to, or in substitution for, STAMP, all in accordance with the Securities Exchange Act of 1934, as amended.
	 	 	 	 
	 	 	 	 
	 	 	Signature Guarantee	 

 

  

  

  

 

Fill in the registration of shares of equity securities, if to be issued, and Notes, if to be delivered, and the person to whom cash and payment for fractional shares is to be made, if to be made, other than to and in the name of the registered holder:

 

Please print name and address

 

______________________________

 

(Name)

 

______________________________

 

(Street Address)

 

______________________________

 

(City, State and Zip Code)

 

Principal amount to be converted

 

(if less than all):

 

$_____________________________

 

Social Security or Other Taxpayer

 

Identification Number:

 

______________________________

 

NOTICE: The signature on this Conversion Notice must correspond with the name as written upon the face of the Note in every particular without alteration or enlargement or any change whatever.ex10_3.htm

Exhibit 10.3

THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD, TRANSFERRED, HYPOTHECATED OR OTHERWISE DISPOSED OF BY THE HOLDER EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT FILED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND IN COMPLIANCE WITH APPLICABLE SECURITIES LAWS OF ANY STATE WITH RESPECT THERETO OR IN ACCORDANCE WITH AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER THAT AN EXEMPTION FROM SUCH REGISTRATION IS AVAILABLE AND ALSO MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH ANY APPLICABLE RULES OF THE SECURITIES AND EXCHANGE COMMISSION.

REGEN BIOLOGICS, INC.

WARRANT CERTIFICATE

 

Warrant to Purchase Stock

 

Date of Issue:  March 11, 2011

This warrant certificate (“Warrant Certificate”) certifies that for value received Sports Medicine Holding Company, LLC or registered assigns (the “Holder”) is the owner of warrants (the “Warrants”), which entitles the Holder thereof to purchase at the Exercise Price (as hereinafter defined), at any time on or before the Expiration Date (as hereinafter defined), a number of shares (the “Warrant Shares”) of Series G Convertible Preferred Stock, $0.01 par value (“Series G Stock”) of ReGen Biologics, Inc., a Delaware corporation (the “Company”), as follows: that number of shares of Series G Stock equal to the principal amount under that certain Note (the “Holder’s Note”), of even date herewith issued to the Holder divided by $3.00.  Capitalized terms used herein and not otherwise defined in this Warrant Certificate shall have the meanings given them in the Subscription and Security Agreement between the Company and the Investor(s) named therein, dated March 11, 2011, (as the same may be amended, restated or otherwise modified from time to time (the “Subscription Agreement”).

1.          Warrant; Exercise Price

 

This Warrant Certificate shall entitle the Holder to purchase the Warrant Shares (in an amount determined as set forth above).  The purchase price payable upon exercise of the Warrants shall be equal to $1.00 per share of Series G Stock (the “Exercise Price”).

 

2.           Condition to Exercise; Expiration Date

 

2.1           The Warrants are exercisable, at any time or times after issuance and on or before the Expiration Date (as hereinafter defined), upon surrender of this Warrant Certificate to the Company together with a duly completed Notice of Exercise, in the form attached hereto as Exhibit A, and payment of an amount equal to the product of the Exercise Price times the number of shares of stock to be acquired.  Payment of the Exercise Price for the Warrant Shares shall be in lawful money of the United States of America, paid by wired transfer or cashier’s check drawn on a United States bank or pursuant to the terms of Section 7.  In the case of exercise of the Warrants for less than all the Warrant Shares represented by this Warrant Certificate, the Company shall cancel the Warrant Certificate upon the surrender thereof and shall execute and deliver a new Warrant Certificate for the balance of such Warrant Shares.

  

  

  

2.2           The term “Expiration Date” shall mean 5:00 p.m. New York time on March 11, 2016 or if such date shall in the State of New York be a holiday or a day on which banks are authorized to close, then 5:00 p.m. New York time the next following date which in the State of New York is not a holiday or a day on which banks are authorized to close.

 

3.           Registration and Transfer on Company Books

 

3.1           The Company shall maintain books for the registration and transfer of the Warrants and the registration and transfer of the shares of stock issued upon exercise of the Warrants.

 

3.2           Prior to due presentment for registration of transfer of this Warrant Certificate, or the shares of stock issued upon exercise of the Warrants, the Company may deem and treat the registered Holder as the absolute owner thereof.

 

3.3           Neither this Warrant Certificate nor the Warrant Shares have been registered under the Securities Act of 1933, as amended (the “Act”).  The Company will not transfer this Warrant Certificate or the Warrants or issue or transfer the Warrant Shares unless (i) there is an effective registration covering such Warrants or Warrant Shares, as the case may be, under the Act and applicable states securities laws, (ii) it first receives a letter from an attorney, acceptable to the Company's board of directors or its agents, stating that in the opinion of the attorney the proposed issue or transfer is exempt from registration under the Act and under all applicable state securities laws, or (iii) the transfer is made pursuant to Rule 144 under the Act.  Subject to the foregoing, this Warrant Certificate, the Warrants represented hereby, and the Warrant Shares, may be sold, assigned or otherwise transferred voluntarily by the Holder to officers or directors of the Holder, to members of such persons’ immediate families, or to the Holder’s parent or subsidiary corporations.  The Company shall register upon its books any permitted transfer of a Warrant Certificate, upon surrender of same to the Company with a written instrument of transfer duly executed by the registered Holder or by a duly authorized attorney.  Upon any such registration of transfer, new Warrant Certificate(s) shall be issued to the transferee(s) and the surrendered Warrant Certificate shall be canceled by the Company.  A Warrant Certificate may also be exchanged, at the option of the Holder, for new Warrant Certificates representing in the aggregate the number of Warrant Shares evidenced by the Warrant Certificate surrendered.

 

  

2

  

 

4.          Reservation of Shares

 

The Company covenants that it will at all times reserve and keep available out of its authorized Series G Stock, solely for the purpose of issue upon exercise of the Warrants, such number of shares of Series G Stock as shall then be issuable upon the exercise of all the Warrants represented by this Warrant Certificate.  The Company covenants that all Warrant Shares shall be duly and validly issued and, upon payment for such shares as set forth herein, fully paid and nonassessable and free from all taxes, liens and charges with respect to the issue thereof, and that upon issuance such shares shall be listed on the national securities exchange, if any, on which the other shares of outstanding Series G Stock of the Company are then listed.

 

5.           Loss or Mutilation

Upon receipt by the Company of reasonable evidence of the ownership of and the loss, theft, destruction or mutilation of any Warrant Certificate and, in the case of loss, theft or destruction, of indemnity reasonably satisfactory to the Company, or, in the case of mutilation, upon surrender and cancellation of the mutilated Warrant Certificate, the Company shall execute and deliver in lieu thereof a new Warrant Certificate representing the number of Warrant Shares evidenced by the lost, stolen, destroyed or mutilated Warrant Certificate.

6.           Adjustments of Exercise Price and Shares

 

6.1           In the event of changes in the outstanding Series G Stock of the Company by reason of dividends, distributions, split-ups, recapitalizations, reclassifications, combinations or exchanges of shares, separations, reorganizations, liquidations, consolidation, acquisition of the Company (whether through merger or acquisition of substantially all the assets or stock of the Company), or the like, the number and class of shares available under the Warrants in the aggregate and the Exercise Price shall be correspondingly adjusted to give the Holder of the Warrants, on exercise for the same aggregate Exercise Price, the total number, class, and kind of shares or other property as the Holder would have owned had the Warrants been exercised prior to the event and had the Holder continued to hold such shares until the event requiring adjustment.  The form of this Warrant Certificate need not be changed because of any adjustment in the number of Warrant Shares subject to this Warrant Certificate or the Exercise Price provided herein.

 

6.2           If at any time or from time to time the holders of all of the shares of Series G Stock of the Company (or the holders of all of the shares of stock or other securities at the time receivable upon the exercise of the Warrants) shall, as a class, have received or become entitled to receive, without payment therefor:

 

	
  

	
(i)

	
Common Stock or any shares of stock or other securities which are at any time directly or indirectly convertible into or exchangeable for Common Stock, or any rights or options to subscribe for, purchase or otherwise acquire any of the foregoing by way of dividend or other distribution (other than a dividend or distribution covered in Section 6.1 above),

 

  

3

  

 

	
  

	
(ii)

	
any cash paid or payable; or

 

	
  

	
(iii)

	
Common Stock or additional stock or other securities or property (including cash) by way of spinoff, split-up, reclassification, combination of shares or similar corporate rearrangement (other than shares of Common Stock pursuant to Section 6.1 above),

 

then, and in each such case, the Holder hereof will, upon the exercise of the Warrants, be entitled to receive, in addition to the number of shares of Series G Stock receivable thereupon, and without payment of any additional consideration therefor, the amount of stock and other securities and property (including cash in the cases referred to in clauses (ii) and (iii) above) which such Holder would hold on the date of such exercise had he or she been the holder of record of such Series G Stock as of the date on which holders of Series G Stock received or became entitled to receive such shares or all other additional stock and other securities and property.

 

6.3           Whenever the number of Warrant Shares purchasable upon the exercise of the Warrants or the Exercise Price of such Warrant Shares is adjusted, as herein provided, the Company shall mail to the Holder, at the address of the Holder shown on the books of the Company, a notice of such adjustment or adjustments, prepared and signed by the Chief Financial Officer, the Secretary or another authorized officer of the Company, which sets forth the number of Warrant Shares purchasable upon the exercise of each Warrant and the Exercise Price of such Warrant Shares after such adjustment, a brief statement of the facts requiring such adjustment and the computation by which such adjustment was made.

 

7.           Conversion

 

7.1           In lieu of exercise of any portion of the Warrants as provided in Section 2.1 hereof, the Warrants represented by this Warrant Certificate (or any portion thereof) may, at the election of the Holder, be converted into the nearest whole number of shares of Series G Stock equal to:  (1) the product of (a) the number of Warrants to be so converted, (b) the number of shares of Series G Stock then issuable upon the exercise of each Warrant and (c) the excess, if any, of (i) the Implied Series G Market Price Per Share (as determined pursuant to Section 8.2 hereof) with respect to the date of conversion minus (ii) the Exercise Price in effect on the business day next preceding the date of conversion, divided by (2) the Implied Series G Market Price Per Share with respect to the date of conversion.

 

7.2           The conversion rights provided under this Section 7 may be exercised in whole or in part and at any time and from time to time while any Warrants remain outstanding.  In order to exercise the conversion privilege, the Holder shall surrender to the Company, at its offices, this Warrant Certificate accompanied by a duly completed Notice of Conversion in the form attached hereto as Exhibit B.  The Warrants (or so many thereof as shall have been surrendered for conversion) shall be deemed to have been converted immediately prior to the close of business on the day of surrender of such Warrant Certificate for conversion in accordance with the foregoing provisions.  As promptly as practicable on or after the conversion date, the Company shall issue and shall deliver to the Holder (i) a certificate or certificates representing the number of shares of Series G Stock to which the Holder shall be entitled as a result of the conversion, and (ii) if the Warrant Certificate is being converted in part only, a new certificate in principal amount equal to the unconverted portion of the Warrant Certificate.

 

  

4

  

 

8.           Fractional Shares and Warrants; Determination of Market Price Per Share

 

8.1           Anything contained herein to the contrary notwithstanding, the Company shall not be required to issue any fraction of a share of Series G Stock in connection with the exercise of the Warrants.  The Warrants may not be exercised in such number as would result (except for the provisions of this paragraph) in the issuance of a fraction of a share of Series G Stock unless the Holder is exercising all the Warrants represented by this Warrant Certificate then owned by the Holder.  In such event, the Company shall, upon the exercise of the Warrants, issue to the Holder the largest aggregate whole number of shares of Series G Stock called for thereby upon receipt of the Exercise Price for all the Warrants represented by this Warrant Certificate and pay a sum in cash equal to the remaining fraction of a share of Common Stock multiplied by the Common Stock Market Price Per Share (as determined pursuant to Section 8.2 below) as of the last business day preceding the date on which the Warrants are presented for exercise.

 

8.2           As used herein, the “Implied Series G Market Price Per Share” with respect to any date shall mean one hundred (100) times the average closing price per share of Company's Common Stock for the ten (10) trading days immediately preceding such date during which the Common Stock has traded.  The closing price for each such day shall be the closing sale price or, in case no such sale takes place on such day, the closing price on the last trading day, in either case on the principal securities exchange on which the shares of Common Stock of the Company are listed or admitted to trading, the last sale price, or in case no sale takes place on any such day, the average of the high and low sales prices of the Common Stock on the Over-the-Counter Bulletin Board (“OTCBB”) or any comparable system, or if the Common Stock is not reported on OTCBB, or a comparable system, the average of the closing bid and asked prices as furnished by two members of the Financing Industry Regulatory Authority selected from time to time by the Company for that purpose.  If such bid and asked prices are not available, then “Implied Series G Market Price Per Share” shall be equal to the fair market value of the Company's Common Stock as determined in good faith by the board of directors of the Company.

 

9.           Notices

 

All notices, requests, demands, claims, and other communications hereunder shall be in writing and shall be delivered by certified or registered mail (first class postage pre-paid), guaranteed overnight delivery, or facsimile transmission if such transmission is confirmed by delivery by certified or registered mail (first class postage pre-paid) or guaranteed overnight delivery, to the following addresses and telecopy numbers (or to such other addresses or telecopy numbers which such party shall subsequently designate in writing to the other party):

 

  

5

  

 

if to the Company to:

 

ReGen Biologics, Inc.

411 Hackensack Avenue

Hackensack, NJ  07601

Attention: Gerald E. Bisbee, Jr., Ph.D.

Telecopy: 201.651.5141

 

with a copy to:

 

Pillsbury Winthrop Shaw Pittman LLP

1650 Tysons Boulevard

McLean, VA 22102

Attention: David C. Main, Esq.

 

Telecopy: 703.770.7901

 

if to the Holder to the address set forth on the books of the Company.

 

Each such notice or other communication shall for all purposes of this Agreement be treated as effective or having been given when delivered if delivered by hand, by messenger or by courier, or if sent by facsimile, upon confirmation of receipt.

 

10.           Governing Law

 

This Warrant Certificate shall be governed by and construed in accordance with the laws of the State of New York.

 

  

6

  

IN WITNESS WHEREOF, the Company has caused this Warrant Certificate to be duly executed as of the date first above written.

 

REGEN BIOLOGICS, INC.

By:  __________________________________

Name: Gerald E. Bisbee, Jr., Ph.D.

Title:   President and Chief Executive Officer

  

7

  

 

EXHIBIT A

 

NOTICE OF EXERCISE

 

	  	
To:

	
ReGen Biologics, Inc.

	  
	  	  	
411 Hackensack Avenue

	
______________, 20_____

	  	  	
Hackensack, NJ  07601

	  

 

The undersigned hereby irrevocably elects to purchase, pursuant to Section 2 of the Warrant Certificate accompanying this Notice of Exercise, _______ Warrant Shares of the total number of Warrant Shares issuable to the undersigned pursuant to the accompanying Warrant Certificate, and herewith makes payment of $___________ in payment in full of the aggregate Exercise Price of such shares.

 

Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

The Warrant Shares shall be delivered to the following:

 

	  	  	  
	  	  	  
	  	  	  
	  	  	  
	  	  	  
	  	  	
Name of Holder

	  	  	  
	  	  	  
	  	  	
Signature

	  	  	  
	  	  	
Address:

	  	  	  
	  	  	  
	 	 	 

 

  

  

  

EXHIBIT B

NOTICE OF CONVERSION

 

	  	
To:

	
ReGen Biologics, Inc.

	  
	  	  	
411 Hackensack Avenue

	
______________, 20_____

	  	  	
Hackensack, NJ  07601

	  

 

The undersigned hereby irrevocably elects to convert, pursuant to Section 7 of the Warrant Certificate accompanying this Notice of Conversion, _______ Warrant Shares of the total number of Warrant Shares issuable to the undersigned pursuant to the accompanying Warrant Certificate into shares of the Common Stock of the Company (the “Shares”).

 

The number of Shares to be received by the undersigned, calculated in accordance with the provisions of Section 7.1 of the accompanying Warrant Certificate, is ________________.

 

Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

The Warrant Shares shall be delivered to the following:

 

	  	  	  
	  	  	  
	  	  	  
	  	  	  
	  	  	  
	  	  	
Name of Holder

	  	  	  
	  	  	  
	  	  	
Signature

	  	  	  
	  	  	
Address:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00187-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00187-of-00352.parquet"}]]